Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - vaxelis
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp63b3f084a70182e692d011ffeb8c1337
identifier: http://ema.europa.eu/identifier
/EU/1/15/1079/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Vaxelis suspension for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-63b3f084a70182e692d011ffeb8c1337
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/15/1079/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - vaxelis
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Vaxelis is a vaccine, which helps to protect your child against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by Haemophilus influenzae type b. Vaxelis is given to children from the age of six weeks. The vaccine works by causing the body to produce its own protection (antibodies) against the bacteria and viruses that cause the following diseases:
As with any vaccine, Vaxelis may not protect 100% of children who receive the vaccine.
To make sure that Vaxelis is suitable for your child, it is important to talk to your doctor or nurse if any of the points below apply to your child. If there is anything you do not understand, ask your doctor, pharmacist or nurse to explain. Do not use Vaxelis if your child:
to Vaxelis vaccine or any diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B or Hib containing vaccines,
to any ingredients listed in section 6,
to glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B (antibiotics) and bovine serum albumin, as these substances are used during the manufacturing process.
had a fever of 40.5 C or above within 48 hours not due to another identifiable cause.
became floppy, unresponsive or unconscious after the previous vaccination, within hours of vaccination.
cried continuously and could not be comforted for more than 3 hours within 48 hours of vaccination.
had a fit (convulsions) with or without fever, within 3 days of vaccination.
Vaxelis will be given to your child by a doctor or nurse trained in the use of vaccines and who are equipped to deal with any uncommon severe allergic reaction to the injection (see section 4 Possible side effects). Your doctor or nurse will inject Vaxelis into your child s thigh (in infants from the age of 6 weeks) or arm (in children older than one year). The recommended dose is as follows: First course of vaccination (primary vaccination) Your child will receive two or three injections given at least one month apart. Your doctor or nurse will tell you when your child should come back for their next injection as per the local vaccination program. Additional injection (booster) After the first course of injections, your child will receive a booster dose, in accordance with local recommendations, at least 6 months after the last dose of the first course. Your doctor will tell you when this dose should be given. If your child misses a dose of Vaxelis If your child misses a scheduled injection, it is important that you discuss with your doctor or nurse who will decide when to give the missed dose. It is important to follow the instructions from the doctor or nurse so that your child completes the course of injections. If not, your child may not be fully protected against the diseases. If you have any further questions on the use of this vaccine, ask your doctor, pharmacist or nurse.
Like all medicines, this vaccine can cause side effects, although not everybody gets them. Serious allergic reactions If any of these symptoms occur after leaving the place where your child received his/her injection, you must consult a doctor IMMEDIATELY:
blueness of the tongue or lips
a rash
swelling of the face or throat
low blood pressure causing dizziness or collapse. When these signs or symptoms occur they usually develop quickly after the injection is given and while the child is still in the clinic or doctor s surgery. Serious allergic reactions are very rare (may affect up to 1 in 10,000 people) and can occur after receiving any vaccine. Other side effects If your child experiences any of the following side effects, please tell your doctor, nurse or pharmacist.
Keep this vaccine out of the sight and reach of children. Store in a refrigerator (2 C - 8 C). Do not freeze. Keep the vaccine in the outer carton in order to protect from light. Do not use this vaccine after the expiry date which is stated on the carton and the label after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Vaxelis contains The active substances per dose (0.5 mL): Diphtheria Toxoid1
not less than 20 IU6 Tetanus Toxoid1
not less than 40 IU6 Bordetella pertussis antigens1 Pertussis Toxoid (PT)
20 micrograms Filamentous Haemagglutinin (FHA)
20 micrograms Pertactin (PRN)
3 micrograms Fimbriae Types 2 and 3 (FIM)
5 micrograms Hepatitis B surface antigen2,3
10 micrograms Poliovirus (Inactivated)4 Type 1 (Mahoney)
40 D antigen units5 Type 2 (MEF-1)
8 D antigen units5 Type 3 (Saukett)
32 D antigen units5 Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate)
3 micrograms Conjugated to meningococcal protein2
50 micrograms 1 adsorbed on aluminium phosphate (0.17 mg Al3+) 2 adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.15 mg Al3+) 3 produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology 4 produced in Vero cells 5 or equivalent antigenic quantity determined by a suitable immunochemical method 6 or equivalent activity determined by an immunogenicity evaluation. Aluminium phosphate and amorphous aluminium hydroxyphosphate sulphate are included in the vaccine as adjuvants. Adjuvants are included to improve the immune response of vaccines. The other ingredients are: Sodium phosphate, water for injections The vaccine may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin, polymyxin B, and bovine serum albumin. What Vaxelis looks like and contents of the pack The normal appearance of the vaccine is a uniform, cloudy, white to off-white suspension, which may settle down during storage. Vaxelis is provided as a suspension for injection in pre-filled syringe. Pack size of 1 or 10 pre-filled syringes, without attached needle, with 1 separate needle or with 2 separate needles. Multipack of 5 packs of 10 pre-filled syringes with no needle. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer MCM Vaccine B.V., Robert Boyleweg 4, 2333 CG Leiden, The Netherlands For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien MSD Belgium T l/Tel: +32(0)27766dpoc_belux@merck.com Lietuva UAB Merck Sharp & Dohme Tel. + 370 5 278 02 msd_lietuva@merck.com
.: +359 2 819 3info-msdbg@merck.com Luxembourg/Luxemburg MSD Belgium T l/Tel: +32(0)27766dpoc_belux@merck.com esk republika Merck Sharp & Dohme s.r.o. Tel: +420 233 010 dpoc_czechslovak@merck.com Magyarorsz g MSD Pharma Hungary Kft. Tel.: +36 1 888 5hungary_msd@merck.com Danmark MSD Danmark ApS Tlf: + 45 4482 4dkmail@merck.com Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) malta_info@merck.com Deutschland MSD Sharp & Dohme GmbH Tel: 0800 673 673 673 (+49 (0) 89 4561 0) e-mail@msd.de Nederland Merck Sharp & Dohme B.V. Tel: 0800 9999(+31 23 5153153) medicalinfo.nl@merck.com
Eesti Merck Sharp & Dohme O Tel.: +372 6144 msdeesti@merck.com Norge MSD (Norge) AS Tlf: +47 32 20 73 msdnorge@msd.no
MSD . . . . . : +30 210 98 97 dpoc_greece@merck.com sterreich Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 dpoc_austria@merck.com Espa a Merck Sharp & Dohme de Espa a, S.A. Tel: +34 91 321 06 msd_info@merck.com Polska MSD Polska Sp. z o.o. Tel: +48 22 549 51 msdpolska@merck.com France MSD France T l: + 33 (0) 1 80 46 40 Portugal Merck Sharp & Dohme, Lda Tel: +351 21 4465inform_pt@merck.com Hrvatska Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 croatia_info@merck.com Rom nia Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 msdromania@merck.com Ireland Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998medinfo_ireland@merck.com Slovenija Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 5204 msd.slovenia@merck.com sland Vistor hf. S mi: + 354 535 7Slovensk republika Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282dpoc_czechslovak@merck.com Italia MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) medicalinformation.it@msd.com Suomi/Finland MSD Finland Oy Puh/Tel: +358 (0)9 804 info@msd.fi
The following information is intended for healthcare professionals only: The pre-filled syringe should be shaken gently in order to obtain a homogeneous, whitish, cloudy suspension. The suspension should be visually inspected, prior to administration, for foreign particulate matter and/or variation of physical appearance. If either is observed, discard the pre-filled syringe. The needle must be fitted firmly on to the pre-filled syringe, rotating it by a one-quarter turn. Vaxelis is for intramuscular injection only. The recommended injection sites are the anterolateral aspect of the thigh or the deltoid region of the upper arm if there is adequate muscle mass. The anterolateral aspect of the thigh is the preferred site for infants under one year of age. Package leaflet: Information for the user Vaxelis suspension for injection in vial Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and Haemophilus type b conjugate vaccine (adsorbed). Read all of this leaflet carefully before your child is vaccinated with this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-63b3f084a70182e692d011ffeb8c1337
Resource Composition:
Generated Narrative: Composition composition-en-63b3f084a70182e692d011ffeb8c1337
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1079/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - vaxelis
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp63b3f084a70182e692d011ffeb8c1337
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp63b3f084a70182e692d011ffeb8c1337
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1079/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Vaxelis suspension for injection in pre-filled syringe
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en